Anixa Biosciences (NASDAQ:ANIX) Director Arnold Baskies Purchases 10,000 Shares of Stock

Anixa Biosciences Inc (NASDAQ:ANIX) Director Arnold Baskies acquired 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 28th. The shares were acquired at an average cost of $3.04 per share, for a total transaction of $30,400.00. Following the completion of the acquisition, the director owned 135,000 shares of the company’s stock, valued at $410,400. This trade represents a 8.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Anixa Biosciences Trading Up 2.3%

Shares of NASDAQ ANIX opened at $3.10 on Friday. Anixa Biosciences Inc has a 12-month low of $2.33 and a 12-month high of $5.46. The stock’s fifty day simple moving average is $3.67 and its two-hundred day simple moving average is $3.59. The stock has a market capitalization of $103.48 million, a PE ratio of -8.86 and a beta of 0.49.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Monday, January 12th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). On average, equities analysts predict that Anixa Biosciences Inc will post -0.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ANIX. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 29th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research report on Friday, December 12th. Finally, Zacks Research lowered Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Anixa Biosciences currently has an average rating of “Hold” and an average target price of $9.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP acquired a new stake in shares of Anixa Biosciences during the second quarter worth $39,000. NewEdge Advisors LLC purchased a new position in Anixa Biosciences in the 2nd quarter worth $33,000. Jane Street Group LLC lifted its position in Anixa Biosciences by 37.2% during the 2nd quarter. Jane Street Group LLC now owns 41,800 shares of the company’s stock worth $138,000 after acquiring an additional 11,340 shares during the period. Benjamin Edwards Inc. acquired a new stake in Anixa Biosciences during the 2nd quarter worth about $37,000. Finally, World Investment Advisors purchased a new stake in Anixa Biosciences during the 3rd quarter valued at about $48,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.